Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heron Therapeutics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

Recent & Breaking News (NDAQ:HRTX)

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

PR Newswire January 21, 2021

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

PR Newswire January 11, 2021

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain

PR Newswire November 13, 2020

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences

PR Newswire November 11, 2020

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates

PR Newswire November 5, 2020

Heron Therapeutics Receives European Commission Authorization for ZYNRELEF(TM) (HTX-011) for the Treatment of Postoperative Pain

PR Newswire September 28, 2020

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

PR Newswire September 16, 2020

Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference

PR Newswire September 11, 2020

Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain

PR Newswire September 8, 2020

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

PR Newswire August 5, 2020

Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain

PR Newswire July 24, 2020

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

PR Newswire July 16, 2020

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

PR Newswire June 29, 2020

Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

PR Newswire June 4, 2020

Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain

PR Newswire May 18, 2020

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020 and Highlights Recent Corporate Updates

PR Newswire May 6, 2020

Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

PR Newswire April 9, 2020

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates

PR Newswire March 2, 2020

Heron Therapeutics to Present at the 40th Annual Cowen Healthcare Conference

PR Newswire February 25, 2020

Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain

PR Newswire February 19, 2020